McDermott and Bull executive Search

Other News

Endologix Honors Innovators of Aortic Therapy at VEITHsymposium

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today honored four innovators of aortic therapy at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium®), a meeting of endovascular specialists highlighting developments in the treatment of vascular disease. At an […]

Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights

MELBOURNE, Australia and NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported strong financial results and provided operational highlights for the first quarter ended September 30, 2018. Key financial results for the three months ended September 30, 2018 (first quarter FY2019) Significant increase in revenues to […]

New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System

DUBLIN and NEW YORK – November 16, 2018 – Medtronic plc (NYSE:MDT) today announced new data on the Heli-FX(TM) EndoAnchor(TM) system, which demonstrated durability, safety and efficacy in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those with hostile aortic neck anatomies. The new data were unveiled in presentations at the […]

From Diagnostics and Delivery to Disease Prevention; Measuring the Impact of AI in Healthcare

by Ken Dropiewski, Principal Consultant – McDermott &Bull Executive Search  Executive Summary: This white paper discussion centers on ways in which three distinct branches of healthcare are currently being impacted by the introduction or use of artificial intelligence (AI). I’ll take a look, via case studies, at various ways AI is […]

CHF Solutions Launches Educational Webinar Discussing the Benefits of Aquadex FlexFlow® Therapy Following Cardiovascular Surgery with Cardiovascular Surgeon, Daniel Beckles, M.D., Ph.D.

EDEN PRAIRIE, Minn., Nov. 15, 2018 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS), today announces the launch of its new educational webinar featuring Daniel Beckles, M.D., Ph.D., director of Minimally Invasive Cardiothoracic Surgery at UHS Heart and Vascular Institute, Vestal, N.Y.  The webinar can be accessed on the company’s […]

Orchestra BioMed™ Announces Completion of $41 Million Financing

NEW HOPE, Pa., Nov. 15, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, today announced the successful final closing of a $41 million private equity financing, which also included the conversion of outstanding […]

ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Nov. 14, 2018 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018 and provided a corporate update. “We remain focused on advancing the […]

New Harmonized Outcome Measures for Atrial Fibrillation Published in HeartRhythm

BOSTON, Nov. 15, 2018 /PRNewswire/ — OM1, a leading health outcomes and technology company, today announced the publication of new harmonized outcome measures for atrial fibrillation (AF) in HeartRhythm.  OM1’s Richard Gliklichand Michelle Leavy collaborated on the development of the measures and co-authored the publication. The work was funded by the Agency for Healthcare Research and Quality (AHRQ) through an […]

Neovasc Announces Third Quarter 2018 Financial Results

VANCOUVER, Nov. 14, 2018 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCNTSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today reported financial results for the third quarter ended September 30, 2018. “In […]

Ra Medical Systems Reports Third Quarter 2018 Results

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED) (the Company), a commercial-stage medical device company leveraging its advanced, minimally-invasive excimer laser-based platform for use in the treatment of vascular and dermatological diseases, today reported its financial results for the three and nine-month period ended September 30, 2018. “The third quarter of […]